Reason for Termination: “Failure to Fulfill Commercialization Obligations, Including Obtaining Product Approval and Conducting Sales”
Daewoong Pharmaceutical to Pursue Entry into Chinese Market Through Beijing Subsidiary

Daewoong Pharmaceutical has terminated its export and supply contract to China for Fexuprazan (product name Pexuclu), a treatment for gastroesophageal reflux disease. The contract was worth approximately 384.5 billion won, equivalent to 36% of the company’s sales at the time, making it a large-scale deal. As a project that had already obtained marketing authorization in China was halted at the commercialization stage, the company has no other choice but to overhaul its local market entry strategy.

Advertising image for Peksukulru, a gastroesophageal reflux disease treatment developed by Daewoong Pharmaceutical. Daewoong Pharmaceutical

Advertising image for Peksukulru, a gastroesophageal reflux disease treatment developed by Daewoong Pharmaceutical. Daewoong Pharmaceutical

View original image

Daewoong Pharmaceutical announced on the 12th, via a regulatory filing, that it has terminated the Fexuprazan supply contract for China that it had signed with Yangtze River Pharmaceutical in China. The reason for termination was cited as the “failure of the counterparty to fulfill its commercialization obligations, including obtaining product approval and conducting sales.” The contract period was from March 2021 to April 2036.


Under this contract, the local partner was responsible for obtaining approval and selling the product in China. At the time of signing, the deal was expected to become a core global pipeline, as its size exceeded 36% of Daewoong Pharmaceutical’s consolidated sales.


Fexuprazan obtained marketing authorization in September last year from China’s National Medical Products Administration (NMPA) for the indication of treating reflux esophagitis. Although the approval stage was completed, it is interpreted that subsequent commercialization procedures, such as establishing production and distribution structures and participating in hospital tenders, did not proceed according to the contractual timeline. Daewoong Pharmaceutical plans to pursue Fexuprazan’s entry into the Chinese market through its Beijing subsidiary going forward.



Fexuprazan, which received domestic marketing authorization in 2019, is the 34th new drug developed in Korea. It is regarded as a case in which a next-generation gastric acid suppressant, developed after conventional proton pump inhibitors, was commercialized using homegrown technology. In a Phase 3 clinical trial conducted in China, its efficacy was compared with that of the standard treatment, esomeprazole, and a similar level of therapeutic effect was confirmed.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing